UCARTFAP
/ Cellectis
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 14, 2021
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
(GlobeNewswire)
- "Cellectis outlines four new UCART preclinical programs, targeting solid tumors: (i) UCARTMUC1 for Mucin 1-expressing epithelial cancers: Preclinical data indicates that UCARTMUC1 shows strong intratumoral expansion translating into promising preclinical anti-tumor activity in vivo; (ii) UCARTFAPtargeting Cancer Associated Fibroblasts (CAFs) in the tumor microenvironment: TCR knocked out to prevent GVHD and beta-2 microglobulin knocked out to provide resistance to the patient’s own T-cells."
Preclinical • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1